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Intracellular protein complexes containing nucleic acids are com-
mon targets of autoantibodies in many autoimmune diseases.
Central tolerance to these antigens is incomplete, yet nucleosomal
DNA is expressed on the surface of cells dying by apoptosis. It is
commonly believed that autoimmunity is prevented by the rapid
uptake of apoptotic cells (ACs) by neighbors or professional
phagocytes to which they deliver anti-inﬂammatory signals. Self-
reactive, innate-like B cells contact and are selected by intracellular
antigens expressed on ACs; however, how self-tolerance is main-
tained is not well understood. Here we report that IL-10 production
by B cells, stimulated by contact with ACs, results from the engage-
ment of Toll-like receptor 9 (TLR9) within the B cell after recognition
of DNA-containing complexes on the surface of ACs. Until now,
TLR9 ligation has been considered an inﬂammatory signal, but we
have conﬁrmed a hitherto unexpected immunoregulatory role by
demonstrating the absence of the protective effect of ACs during
experimental autoimmune encephalitis (EAE) in TLR9-deﬁcient
mice. Human circulating CD27+ B cells also respond to DNA-bearing
ACs, but not to DNase-treated cells, by secreting IL-10. Chronic au-
toimmune disease may arise if this tolerance mechanism is not
reimposed after episodes of inﬂammation, or if the regulatory
B-cell response is subverted.
Apoptotic cells (ACs) are immunomodulatory, dampeningthe inﬂammation mediated by innate immune cells (1–5).
ACs also protect mice from autoimmune-mediated inﬂammation
(6, 7) and induce B cells to adopt an IL-10–secreting regulatory
B-cell phenotype (Breg) (8). Innate-like B cells have many self-
reactive B-cell receptors (BCRs) and are selected by intracellular
antigens expressed on ACs (9), but this is generally compatible
with health (10–13). However, ACs express many of the antigens
associated with autoimmune disease on their cell surface (14–17)
and thus are thought to be a target of autoimmune responses.
The BCR can deliver chromatin complexes from the AC to
the endosome, allowing Toll-like receptor 9 (TLR9)-mediated
signaling (18, 19). Despite this, lupus-related renal disease is
exacerbated in TLR9-deﬁcient mice (20–23), suggesting a regu-
latory role for TLR9-induced activation of self-reactive B cells in
health that breaks down when tolerance is lost, leading to au-
toimmunity (24, 25).
How B cells maintain tolerance to AC-expressed antigens is not
known and is the focus of the present work.We show that marginal
zone B (MZB) cells and B1a B cells recognize DNA-containing
chromatin complexes and secrete IL-10 in response to signaling
through TLR9. In vivo, mice given DNase-treated ACs are no
longer protected from arthritis, and AC-mediated protection from
experimental autoimmune encephalitis (EAE) is lost in TLR9-
deﬁcient mice. In agreement with previous studies (26, 27), we
found that human circulating CD27+ B cells secrete IL-10 in re-
sponse to DNA complexes expressed by ACs. Thus, in health,
TLR9-mediated recognition of ACs by B cells allows maintenance
of tolerance to self.
Results
IL-10 Production by B Cells Requires Direct Contact with Whole ACs
but Is Absent in B Cells Speciﬁc for Hen Egg Lysozyme. B cells secrete
IL-10 in response to ACs, but only when they are able to make
direct contact with whole ACs rather than with cellular debris (Fig.
S1 A and B). Little IL-10 protein is detectable when resting B cells
are coculturedwithACs, although themajority of B cells die rapidly
in culture in the absence of concomitant stimulation (28) (Fig.
S1D). To address this in another way, we injected ACs into IL-10
reporter mice and 1 wk later analyzed IL-10 secretion from splenic
MZB cells by FACS analysis. We found IL-10 expression in 5.15%
of the MZB cells from mice that had received vehicle alone (Fig.
1A), and in 14.1% of theMZB cells in mice that had received ACs,
indicating that B cells can respond to ACs in vivo in the absence of
additional stimulation. In addition, short-term cocultures of MZB
cells andACs alone induced a fourfold increase inmRNA for IL-10
(Fig. 1B), again showing that B cells can respond to ACs in the
absence of additional stimuli. The IL-10 protein level increased
further when the B cells were activated by T cells or TLR ligands.
MZB and B1 B cells cocultured with ovalbumin (OVA)-speciﬁc
T cells, OVA peptide, and ACs secreted signiﬁcantly more IL-10
compared with those in cultures containing follicular B (FOB)
cells (Fig. 1 C andD and Fig. S1 C andD), which lack self-reactive
BCRs (29). However, IL-10 secretion was not enhanced in FOBs
and MZB cell populations drawn from BCR transgenic (MD4)
animals carrying a single hen egg lysozyme (HEL) speciﬁcity (30)
not expressed by the ACs (even whenHEL was included in in vitro
cultures) (Fig. 1 C and D). To further clarify the role of the BCRs,
we used SWHEL Ig knock-in mice that have a large proportion of B
cells speciﬁc for HEL, but these can class switch, and these mice
also contain populations of polyclonal B cells (31). MD4 and
SWHELmice have an increased number of MZB cells, but their B1
B cells maintain a FOB phenotype (Fig. S1 E–G). When highly
puriﬁed MZB cells from SWHEL mice were separated into poly-
clonal HEL− and HEL+ MZB cells, only polyclonal MZB cells
produced signiﬁcantly higher amounts of IL-10 in response to ACs
and stimulation with the TLR ligands LPS and peptoglycan (PGN)
(Fig. 1E). This suggests that MZB cells with a polyclonal BCR
repertoire are required for the induction of IL-10 after the rec-
ognition of ACs. In WT mice, B1a B cells (i.e., CD5+) secreted
more IL-10 in response to ACs compared with B1b B cells (CD5−)
(Fig. 1F). However, in cocultures with ACs, activated splenic
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CD1dhiCD5+ and CD1dhiCD5− MZB cells responded similarly
(Fig. 1G and Fig. S1I), suggesting that IL-10 secretion in response
to AC is not restricted to a small subset of splenic B cells with
deﬁned cell surface markers.
DNase Treatment Abolishes the Capacity of ACs to Enhance IL-10
Secretion and Inhibits Regulatory Responses in Vivo. After apoptosis,
chromatin complexes containing DNA are rapidly translocated to
the AC surface (14). Given that recognition of CpG DNA motifs
is a potent inducer of IL-10 in B cells (32), we reasoned that
DNA-bearing molecular patterns on ACs are a potential candi-
date for recognition by Bregs. DNase treatment of ACs removed
DNA from the surface of ACs (Fig. 2A and Fig. S2A) and abol-
ished the AC-mediated enhancement of IL-10 production when
these cells were used in cocultures with OVA-speciﬁc DO11.10 T
cells, OVA peptide, and B cells (Fig. 2B). This effect was speciﬁc
for DNA but not for RNA-containing complexes (Fig. S2B).
DNase-treated ACs also offered no protection in the mouse
model of collagen-induced arthritis (CIA) in contrast to mice
given untreated ACs (Fig. 2C), which was conﬁrmed histologically
(Fig. 2D). The level of protection were correlated with the amount
of IL-10 secreted by spleen cells after in vitro restimulation with
collagen (Fig. 2E). This provides clear evidence that DNA-bearing
molecular patterns expressed on the surface of intact ACs are
responsible for signaling the production of IL-10 by B cells.
B-Cell TLR9 Signaling Is Required for Immunosuppressive Responses
to ACs. After endocytosis, DNA is sensed by several innate recep-
tors (33). One of these, the MyD88-dependent receptor TLR9,
recognizes mammalian DNA in endosomes and requires acidiﬁ-
cation of that compartment for signaling to occur (34). Chloro-
quine, which inhibits endosomal acidiﬁcation, prevents signaling
through TLR7 and TLR9 but not through TLR1, TLR2, or TLR4
(Fig. S3A). When B cells were stimulated with TLR2 (PGN) and
TLR4 (LPS), chloroquine inhibited the AC-induced enhancement
of IL-10 secretion (Fig. 3A). B cells deﬁcient in TLR9 or its
MyD88 signaling adapter (but not in TLR2 or TLR4) also were
unable to induce a signiﬁcant rise in IL-10 secretion in cocultures
with T cells (TLR9/MyD88-sufﬁcient DO11.10 plus pOVA) when
exposed to ACs (Fig. 3B and Fig. S3B). To conﬁrm that this result
is a direct effect of TLR9 signaling on B cells, TLR9-deﬁcient B1
cells were stimulated with TLR4 or TLR2 with and without ACs;
the cells failed to respond to ACs by secreting IL-10 (Fig. 3C).
Clearly, to substantiate an immunosuppressive, regulatory role
for B-cell TLR9, we needed to examine in vivo the effects of TLR9
deﬁciency on AC suppression of autoimmunity. We used myelin
oligodendrocyte glycoprotein (MOG) peptide to induce EAE in
TLR9−/− and TLR9+/+mice, with ACs given at the time of disease
induction. Here ACs were able to confer protection only in the
WT mice, conﬁrming a crucial role for TLR9 in mediating pro-
tection (Fig. 3D). Restimulation of spleen cells from the mice with
EAE on day 12 demonstrated that TLR9-deﬁcient mice made
signiﬁcantly less IL-10, but more proinﬂammatory IL-6 and IL-17
(Fig. S3C). Importantly, when TLR9-deﬁcient mice were injected
with WT B cells (but not TLR9−/− B cells) along with the ACs at
the time of EAE induction, the protective phenotype of ACs was
restored (Fig. 3D and Fig. S3D).
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Fig. 1. Regulatory B cells from the MZB cell and B1a cell subsets recognize whole ACs via the BCRs and secrete IL-10. (A) IL-10–GFP reporter mice were
injected with 20 × 106 ACs, and MZB cells were harvested 1 wk later. IL-10 expression was determined by FACS analysis. (B) MZB cells were stimulated with ACs
for up to 4 h in the absence of further stimulation and mRNA for IL-10 measured by quantitative PCR. (C) B cells from WT or transgenic B cells from mice
speciﬁc for HEL (MD4) were separated into FOB and MZB cells. After stimulation for 72 h in the presence of OVA-speciﬁc transgenic T cells and OVA peptide
with or without ACs, supernatants were collected and IL-10 was measured by ELISA. (D) MZB cells from MD4 and WT mice stimulated as in C, but with the
cognate protein HEL added to some of the cultures. (E) Polyclonal MZB cells (HEL−) and HEL-speciﬁc MZB cells (HEL+) derived from the same SWHEL mice were
stimulated with the TLR4 ligand LPS or the TLR2 ligand PGN for 72 h with and without ACs, and IL-10 was measured. *Indicates a signiﬁcant difference
between IL-10 in stimulated B cells cocultured with ACs and HEL− and HEL+ MZB cells. (F) Peritoneal-derived (PEC) CD5− and CD5+ CD19 B cells and splenic MZB
and FOB cells were stimulated as in C. (G) MZB cells were sorted into CD1dhiCD5− or CD1dhiCD5+ve subsets and stimulated for 72 h as in C (OVA) or with
various TLRs, including CpG (TLR9), R848 (TLR7), and PGN (TLR2), and IL-10 was measured after 72 h. Each ﬁgure is representative of at least three experiments
performed with three mice per group. Error bars represent SEM. ***P ≤ 0.0004; **P ≤ 0.004; *P ≤ 0.04. The threshold for detection of IL-10 was 25 pg/mL.
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Human B Cells Generate an IL-10 Response After Interaction with ACs
That Is Prevented by DNase Treatment. Finally, we asked whether
human B cells also secreted IL-10 in response to DNA-bearing
molecular patterns on ACs. We cocultured peripheral blood B
cells (derived from healthy volunteers) with ACs and IL-4 to
prevent B-cell apoptosis (28). CD27+ B cells secreted signiﬁcantly
more IL-10 (Fig. 4A). This increase did not occur when chloro-
quine (Fig. 4C) or DNase (Fig. S4A) was included in the cocul-
tures, suggesting that both human andmouse Bregs are dependent
onDNA-containing complexes expressed on ACs to secrete IL-10.
Discussion
Healthy mice and humans exhibit signiﬁcant autoreactivity to self-
antigens expressed on ACs, especially within the MZB and B1 B-
cell repertoires (12, 13, 35, 36). Themechanism by which tolerance
is maintained in these peripheral B-cell populations has remained
obscure, although these cells are able to contact and be selected by
intracellular antigens expressed by ACs (37). Likewise, the
mechanism by which regulatory function can be imparted to B cells
by interaction with ACs is not known. In this paper, by way of
explanation, we ﬁnd that DNA-containing complexes on the sur-
face of whole ACs are sensed by Bregs and delivered to TLR9-
containing endosomes, where they induce IL-10 secretion. This
provides a means for tolerizing self-reactive B and T cells, as well
as modulating the severity of ongoing immune responses. For full-
memory T-cell responses to occur, T cells must interact with both
dendritic cells (DCs) and antigen-speciﬁc B cells (38, 39). Indeed,
the role of B cells in shaping the T effector response through an-
tigen presentation, costimulation, and cytokine production is being
increasingly recognized (40). However, DCs that ingest infected
ACs are able to up-regulate costimulatory molecules and to ef-
fectively present antigens derived from the ACs (41). Therefore,
after an infectious insult, DCs are at risk of activating self-reactive
T cells. Of note, our data clearly show that Bregs secrete IL-10 in
response to ACs despite the presence of activating stimuli, and
thus they are able tomediate a dominant tolerogenic signal despite
an inﬂammatory milieu, which should ensure that self-reactive T
cells that have been primed by DCs are induced to become regu-
latory IL-10–secreting cells when they contact Bregs.
Our ﬁnding that HEL-speciﬁcMZB cells fromMD4 and SWHEL
mice are refractory to the regulatory effects of ACs leads us to
speculate that self-reactive BCRs are responsible for the recogni-
tion and uptake of these chromatin complexes. Both of these
subsets are replete with self-reactive BCRs (42, 43) and AC DNA,
which is more hypomethylated than DNA from viable cells (44),
can activate TLR9 (45), even though TLR9’s endosomal location
was previously thought to prevent its “accidental” stimulation by
self-DNA (46). Despite this, the regulatory responses of B cells to
ACs were abolished after treatment with chloroquine, which is
known to prevent TLR7 or TLR9 signaling in the endosomal
compartment, but not signaling through other TLRs (Fig. S3A).
Although CpG is able to gain access to the B cells independent of
the BCRs and can induce B cells to secrete cytokines and pro-
liferate (32), recent studies have demonstrated that B cells cannot
take up longer lengths of DNA found physiologically, unless they
are initially internalized through the BCRs (47). This will prevent
large-scale activation of TLR9+memory B cells in vivo and restrict
this activation to self-reactive B cells. In fact, ligation of BCRs have
been shown to control the subcellular distribution of TLR9 in B
cells, allowing relocation of TLR9 from the endoplasmic reticulum
to the endosomal compartment, where interaction with antigen
internalized through the BCRs can occur (48, 49). This again adds
substance to the hypothesis that regulatory responses to AC-
expressed chromatin complexes occurs via the BCRs.
Human CD27+ B cells respond to ACs by secreting IL-10, but
only in the presence of DNA-containing chromatin complexes on
the ACs, which also may help maintain peripheral tolerance in
humans. The conclusion that TLR9 is involved in preventing the
development of potentially damaging autoreactive responses ﬁts
with the observations from mouse disease models. Treatment of
mice with CpG to stimulate TLR9 has alleviated disease severity in
colitis, arthritis, and diabetes (50–53). In addition, lupus-related
renal disease is exacerbated in TLR9-deﬁcient autoimmune prone
mice (20–23), and recent reports suggest that TLR9 is required to
prevent pathological responses that result from TLR7-mediated
signaling (24, 25). Other studies, however, show that TLR9 stim-
ulation has an adjuvant effect driving Th1 responses allied with
IgG2a antibodies, thereby potentially exacerbating autoimmune
disease (19, 54–57). In addition, hydroxychloroquine is used to
good effect in patients with systemic lupus erythematosus and
rheumatoid arthritis, which suggests that in the rheumatic diseases,
autoreactive B cells, which do not have regulatory activity, domi-
nate the immune response.
Thus, it seems likely that TLR9 can mediate both proinﬂam-
matory and immunoregulatory signals, depending on the context
in which the DNA is sensed.What factors might lead to changes in
the balance between regulatory and inﬂammatory responses? The
experiments that ascribe an inﬂammatory response of AC-derived
DNA to TLR9 (19, 54, 55), in which DNA-antibody (IgG2a)
complexes are taken up by rheumatoid factor-expressing B cells,
may represent one of the situations that leads to autoimmune
disease, for instance, when one ormore of these low-afﬁnity B cells
receives signals that allow afﬁnity maturation and drive antibody
A B
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Fig. 2. DNase treatment abolishes the capacity of AC to enhance IL-10 se-
cretion and inhibits regulatory responses in vivo. (A) ACs expressed DNA-
containing complexes, stained with Sytox (molecular probes, Invitrogen) on
the cell surface, which was lost after treatment with DNase. (B) B cells were
stimulated by OVA-speciﬁc T cells, OVA peptide, and ACs along with 50 μg/
mL of DNase, and IL-10 was measured in supernatants after 72 h. (C) A single
injection of vehicle (PBS) or ACs pretreated with DNase (DNase-AC) or un-
treated ACs (AC) was injected into mice at the time of immunization with
type II collagen (CII) in complete Freund’s adjuvant (CFA), and arthritis was
assessed clinically. (D) Histology of H&E-stained sagittal sections through the
knee joints of mice taken from Fig. 3C. Both the DNase-treated mice and the
PBS-treated mice exhibited active synovitis associated with a ﬁbrinopurulent
exudate within the joint space, with less inﬂammation in the AC-treated
mice. (E) Splenocytes from AC-treated mice (ﬁlled squares), DNase-treated
mice (open squares), and WT mice (ﬁlled circles) obtained at the end of the
experiment shown in Fig. 3C were restimulated in vitro with CII for 3 d, and
IL-10 levels were measured. The CIA experiment is representative of two
experiments with eight mice per group. The remaining ﬁgures are repre-
sentative of at least three experiments performed with three mice per
group. Error bars represent SEM. ***P ≤ 0.0004; **P ≤ 0.004; *P ≤ 0.04.
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production. Alternatively, the difference might be quantitative
(e.g., amount of TLR9 ligand delivered as a result of antibody af-
ﬁnity) or qualitative (e.g., availability of T-cell help or the form of
the TLR9 ligand). Interestingly, the delivery of IgG2a–chromatin
complexes to B cells causes proliferation, but not cytokine pro-
duction (49), in contrast to the B cell response to ACs, which
results in both effects (Fig. S4B). Another factor inﬂuencing the
inﬂammatory/regulatory balance is the underlying genetic control
of TLR9 expression and function. A study of Japanese patients
reported lower expression of TLR9 in patients with systemic lu-
pus erythematosus (58). In addition, components of the innate
immune system, such as C1q (59–62) and natural IgM (6), may
decorate DNA-associated molecular patterns on ACs, which can
alter the way DNA complexes are sensed within the endosome.
In summary, our data suggest that naturally occurring MZB and
B1a B cells bind and internalize chromatin complexes from the
surface of ACs, which invokes both B cell proliferation and IL-10
secretion. We believe that this effect provides a regulatory
mechanism to prevent the differentiation of low-afﬁnity autor-
eactive B cells and also obviates any autoimmune consequence of
antigen presentation by these cells. Thus, in health these self-re-
active B cells are kept in check and perform a TLR9-dependent
broad-based tolerance function, but circumstances can cause them
to switch from a regulatory mode to a pathogenic mode. A failure
along the pathway from AC recognition to TLR9 signaling may be
the crucial switch between health and disease secondary to auto-
immunity. Clearly when this layer of immune regulation breaks
down, self-reactive B cells may start to secrete high-titer, high-af-
ﬁnity antibody to apoptotic self, amplifying an autoinﬂammatory
loop and leading to the multitudinous symptoms that characterize
the rheumatic diseases.
Materials and Methods
Cell Stimulation and Treatments. Cells were treatedwith the following: DNase,
50 μg/mL (Roche); Rnase, 10 μg/mL (Sigma-Aldrich); chloroquine, 2 μg/mL
(Sigma-Aldrich); TLR1/2 (PAM(3)CSK), 0.2 μg/mL (InVivoGen); TLR4 ligand LPS,
2 μg/mL (Sigma-Aldrich); TLR3 ligand (poly IC), 25 μg/mL (InVivoGen); TLR2
ligand peptidoglycan, 10 μg/mL (InVivoGen); TLR7 ligand R848, 0.1 μg/mL
(InVivoGen); and TLR9 ligand CpG (ODN 1826) (InVivoGen), 1 μg/mL except in
one experiment in which a dose of 25 μg/mL was used (Fig. S1D). Biotinylated
HEL protein was used at 5.8 μg/mL.
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Fig. 3. B-cell TLR9 signaling is required for the immunosuppressive response to ACs. (A) B cells were stimulated with the TLR ligands PGN (TLR2) and LPS
(TLR4) alone or in the presence of ACs or ACs and chloroquine (AC Chloro) for 72 h, after which IL-10 in the supernatants was measured. (B) WT, MyD88-
deﬁcient (MyD88), and TLR9-deﬁcient (TLR9) B cells were cocultured with ACs, OVA-speciﬁc T cells, and OVA peptide in vitro. After 72 h, IL-10 secretion was
measured by ELISA. (C) PEC B1 cells were stimulated with the same TLR ligands as in Fig. 1Awith and without AC for 72 h, and IL-10 was measured. (D) WT and
TLR9-deﬁcient mice were immunized with MOG/CFA, and EAE was scored. A single i.v. injection of ACs also was administered on day 0. Some TLR9-deﬁcient
mice also received an injection of 10 × 106 CD19 B cells on day 0. The EAE experiment is representative of three experiments with ﬁve mice per group. The
remaining ﬁgures are representative of at least three experiments performed with three mice per group. Error bars represent SEM. ***P ≤ 0.0004; **P ≤
0.004; *P ≤ 0.04. The threshold for detection of IL-10 was 25 pg/mL.
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Fig. 4. Human CD27+ B cells respond to ACs by secreting IL-10. (A) Human
B cells isolated from healthy volunteers were separated into CD27+ and CD27−
fractions and cultured in the presence of IL-4 for 3 d with AC (+AC) or without
AC, after which IL-10 in the supernatants was measured. (B) B cells were
stimulated with ACs and IL-4 in the presence of increasing concentrations of
chloroquine for 3 d, and IL-10 secretion was measured by ELISA. A shows data
collected from 14 healthy volunteer blood donors; B is representative of at
least two separate experiments. Error bars represent SEM. ***P≤ 0.0004; **P≤
0.004; *P ≤ 0.04. The threshold for detection of IL-10 was 25 pg/mL.
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Mice. DO.11.10 TcR transgenic mice (H2Ad-restricted, OVA peptide 323–339-
speciﬁc) (63), MD4 HEL-speciﬁc BCR transgenic mice (30), IL-10–GFP mice (64),
TLR9−/− mice, (56) and MyD88−/− mice (65) were bred and maintained under
speciﬁc pathogen-free conditions in the animal facilities at the University of
Edinburgh. The IL-10–GFPmicewere kindly provided byDr Richard Flavell (Yale
University, New Haven, CT), and the TLR2−/−, TLR4−/−, TLR9−/−, and MyD88−/−
mice were all generously provided by Prof. S. Akira (Hyogo College of Medi-
cine, Nishinomiya, Japan). The SWHEL mice were a kind gift from Dr. Robert
Brink (Garvan Institute, Darlinghurst, NSW, Australia) (31). Male DBA1 mice
were purchased fromHarlan, and C57BL/6 and BALB/cmicewerebred in house.
Mice were used at 8–12 wk of age and were age- and sex-matched in experi-
ments. All experiments were covered by a project license granted by the Home
Ofﬁce under the Animal (Scientiﬁc Procedures) Act of 1986. Locally, this license
was approved by the University of Edinburgh’s Ethical Review Committee.
Cell Isolation and Culture. Human mononuclear cells were extracted from the
peripheral blood of healthy volunteers or from blood donor buffy coats using
dextran sedimentation and a Percoll gradient as described previously (66) with
Lothian Research Ethics Committee approval (LREC/2001/4/56). CD19+ B cells
were isolated in accordance with the manufacturer’s instructions using a neg-
ative selection kit (Miltenyi Biotech). Viable CD19+ B cells were further sorted
into CD27+, CD27−, IgM+, and IgM− subsets using a FACSAria cell sorter (BD
Biosciences) to generate highly puriﬁed populations. Human B cells (3 × 105)
were cocultured with ACs (1 × 106) in the presence of 10 ng/mL of IL-4 for 72 h
in RPMI medium supplemented with FCS. CD4+ T cells and CD19+ B cells from
single-cell suspensions of spleen or lymphnodeswere separated using CD4 and
CD19 microbeads, respectively (Miltenyi Biotech), in accordance with the
manufacturer’s instructions. In some experiments, viable CD19+ B cells were
further separated into FOB and MZB B cells after staining with anti-CD21 and
anti-CD23, and PEC cells were separated into CD5+/− cell populations by cell
sorting with a FACSAria. For experiments with SWHEL mice, viable
CD19+CD23−CD21+ B cells (MZB cells) were further stained with biotinylated
HEL protein and sorted to high purity to yield HEL+- and HEL−-speciﬁc B cells.
Cytokine Quantiﬁcation. Single-cell spleen suspensions were cultured at 5 × 106
cells/mL with serial dilutions of CII, OVA peptide (OVA323–339; Albachem), or
MOG peptide for 72 h in a volume of 200 μL in 96-well round-bottomed plates
(Costar; Corning Life Sciences). For T- and B-cell coculture, T and B cells were
sorted to >98% purity using anti-CD4 and anti-CD19 magnetic beads (Milte-
nyi), and then 2 × 105 B cells were pulsed with peptide and incubated with
1 × 105 DO11.10 CD4+ T cells. Cytokines were quantitated using standard
ELISA (R&D Systems). Transwell plates were purchased from Corning Life Sci-
ences. All experiments were performed in triplicate. Using the optimized kits
(R&D Systems), the threshold for detection was 25 pg/mL for IL-10, 7.8 pg/mL
for IL-6, and 3.9 pg/mL for IL-17.
Generation of ACs.Apoptoticmouse thymocytesweregeneratedby incubating
cells for 4 hwith 0.5 μMdexamethasone, followed by extensivewashing. For in
vivo experiments, ACswere injected i.v. For in vitro cultures, ACswere added to
B cells at a 5:1 ratio and then left in the wells for the duration of the assay.
Induction of CIA. CIA was induced as described previously (8). The ﬁrst signs of
arthritis appeared between day 21 and day 35, with a prevalence of 60–90% of
immunized mice. Each arthritic limb was scored by an investigator blinded to
the treatment regimen as 0, normal; 1, erythema or swelling in a single digit; 2,
erythema and swelling in two or more joints; or 3, swelling of whole paw, in-
cluding the hock joint. The scores of all four jointswere added together, and the
sumwas taken as ameasure of the degree of arthritis, with amaximumpossible
score of 12 (i.e., 4 × 3). For groups, the mean of this score was calculated.
Induction and Assessment of EAE. EAEwas induced by s.c. injection of 100 μg of
MOG peptide (35–55: (MEVGWYRSPFSRVVHLYRNGK) emulsiﬁed in CFA con-
taining 500 μg of heat-killed Mycobacterium tuberculosis H37RA (Sigma-
Aldrich). Mice were given 200 ng of pertussis toxin (Speywood Pharmaceut-
icals) on days 0 and 2, and 20 × 106 ACs i.v. on day 0. Clinical signs of EAE were
assessed daily on a scale of 0 to 6: 0, no signs; 1,ﬂaccid tail; 2, impaired righting
reﬂex and/or gait; 3, partial hindlimb paralysis; 4, total hindlimb paralysis; 5,
hindlimb paralysis with partial forelimb paralysis; 6, moribund or dead.
Histology. Hindlimbs were prepared as described previously (16). Sections
were analyzed blind by a histopathologist (D.S.).
Statistics. Data are expressed, when appropriate, as mean ± SEM. Signiﬁcance
was assessed using unpaired t tests, and P values <0.04 are considered
signiﬁcant.
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